EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. - Wikidata - wikimedia - TriplyDB

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

http://www.wikidata.org/entity/Q35163679

about

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2 Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation The Polymorphisms with Cataract Susceptibility Impair the EPHA2 Receptor Stability and Its Cytoprotective Function Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.Novel anti-EPHA2 antibody, DS-8895a for cancer treatment.Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.Somatic driver mutations in melanoma.EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1.Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling.EphA2 signaling is impacted by carcinoembryonic antigen cell adhesion molecule 1-L expression in colorectal cancer liver metastasis in a cell context-dependent manner.One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2.Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner.Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer.Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies.

P2860

Q26795735-7945A17F-7BC8-417A-A79D-D9BA0253A677 Q28115187-A621A504-3390-4803-9BCE-71A295842B6E Q28116202-3B4423FC-9296-4108-BC97-808543769DD1 Q28395504-4C8BE58D-475D-426A-8A4E-97F9E4008462 Q33588217-D36DAEB5-0DCF-4C00-B8C0-F4FCDA995EDD Q35983871-0C90E683-B5C1-44E0-A097-3CCC1B6E74EE Q37473163-67A035E8-4586-4A71-8EB0-1935FEC53A19 Q37741262-1C9B634D-8CF6-418D-88E6-983286BB36C0 Q38439387-77E21ED7-5C67-4485-8379-A2109FAAFAA4 Q38764368-170E5547-9490-4276-8418-EDF63FC489B0 Q38805633-4BAA125B-13C4-453A-A189-2C4B32BC4E52 Q38849622-CC0F2DC9-BA83-4DB2-83B3-24D65E95BBCC Q41235149-E811C0A9-9E1D-406D-9211-49BD82B828FB Q42358221-424C4F0B-5CA9-4BC3-ACFC-52113D0FAA2A Q47143187-0D648D22-C681-49D9-91B0-4252D52C5EF6 Q47158629-86494E77-C700-4975-A200-FC42B412BE8C Q47431602-BA61F584-A107-49A5-B494-8D4CB3077B77 Q48722415-99ECA396-9797-4837-8197-DCDBBACB90D2 Q50232638-8B0C2EC7-1CBA-425F-8FAE-6CE0C3B63CBA Q54192833-F7144D6F-5777-49DE-9793-AFFA52235CC2 Q54978342-CC93F7BF-EE0F-471D-89F7-6667EAA1BF22

P2860

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

http://www.wikidata.org/entity/Q35163679

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@ast

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@en

type

label

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@ast

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@en

prefLabel

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@ast

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@en

P1433

Q35163679-964A7969-B966-482D-91F2-0E02460E6618

P1476

Q35163679-F62ED055-1026-4725-9298-648B4370A3EB

P2093

Q35163679-02C1121E-6134-4DF3-A2C6-8C6C6B1EB97C

Q35163679-065658E3-4C1D-4C07-AEFA-080BA9BE2FD2

Q35163679-169AC152-6730-43B1-BA8A-AFFD3BE4A852

Q35163679-2907B47A-1383-4644-B45B-574777A0E4E6

Q35163679-2E3CACDA-1995-43ED-AF49-3C55C121E3FA

Q35163679-30BB2638-BB05-48A6-80AC-586668706EF9

Q35163679-30F17304-9C28-48E2-BD3A-D95F9391EDE6

Q35163679-880DE261-E2BF-44A1-BB9B-A1D8A5944A97

Q35163679-A3FB3BBB-DF0B-4672-995A-8A217A71F928

Q35163679-CB0DA9D2-6856-4428-AC34-F8C69FEC8A08

P2860

Q35163679-00C8F8EB-8E22-4624-A4D7-91E0ED00304A

Q35163679-0D9FC01D-8F48-4C2F-B963-99B7421C3928

Q35163679-17A3A87B-F718-4C1C-A749-DF5DA870F317

Q35163679-21BA9C05-4E7F-43B0-8DAD-29B1B6C540B8

Q35163679-27D3901E-47E3-4D94-9F77-DDA16F19D6F9

Q35163679-2881A2F6-BD56-4F76-B9B9-67FA89E2AD1C

Q35163679-2A391785-AA86-4AB3-9831-B4E4A0A1DAB4

Q35163679-2B56E041-C55C-4D09-85CB-38E17C0809C6

Q35163679-2E732E6E-1666-4C1B-B532-93D92A664252

Q35163679-34CC4186-AAB3-4FAE-B3FF-F84E6B50F36A

P304

Q35163679-1481A656-8166-4CA8-A0F9-E4E7DB810C27

P31

Q35163679-EBCAEC56-EA3C-4F39-BCB9-D157796EE1C8

P356

Q35163679-ED5E824B-9FFC-4EC1-9045-2D883E6F2BDF

P433

Q35163679-355F116E-91B1-4F7D-B342-8886E0EA742B

P478

Q35163679-C39ADBD0-76A7-4B95-BE86-47F78BB3F488

P50

Q35163679-73314752-9CB6-4291-8DDB-81830C6F424E

P577

Q35163679-C8C7826D-99BA-4537-89D1-2FBE86D32348

P698

Q35163679-AE65468E-B79F-4E1F-AC5A-AD2E316E31BE

P932

Q35163679-79036FDD-083D-4336-B5D0-2840D8EDAF53

P356

2159-8290.CD-14-0295

P1433

Cancer Discovery

P1476

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

@en

P2093

Benchun Miao

http://www.w3.org/2001/XMLSchema#string

Dennie T Frederick

http://www.w3.org/2001/XMLSchema#string

Hensin Tsao

http://www.w3.org/2001/XMLSchema#string

Hwan Geun Choi

http://www.w3.org/2001/XMLSchema#string

Jennifer A Wargo

http://www.w3.org/2001/XMLSchema#string

Jianming Zhang

http://www.w3.org/2001/XMLSchema#string

Li Tan

http://www.w3.org/2001/XMLSchema#string

Michael Taylor

http://www.w3.org/2001/XMLSchema#string

Nathanael S Gray

http://www.w3.org/2001/XMLSchema#string

Raj Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation

EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt

The expression of the receptor-protein tyrosine kinase gene, eck, is highly restricted during early mouse development

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Ephs and ephrins in cancer: ephrin-A1 signalling

Melanoma: from mutations to medicine

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

P304

274-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-14-0295

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25542448

http://www.w3.org/2001/XMLSchema#string

P932

4355085

http://www.w3.org/2001/XMLSchema#string